Scotiabank Initiates Coverage On INmune Bio with Sector Outperform Rating, Announces Price Target of $22
Portfolio Pulse from Benzinga Newsdesk
Scotiabank has initiated coverage on INmune Bio with a Sector Outperform rating and set a price target of $22.
August 22, 2024 | 12:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Scotiabank has initiated coverage on INmune Bio with a Sector Outperform rating and a price target of $22, indicating a positive outlook.
The initiation of coverage with a Sector Outperform rating and a price target of $22 by Scotiabank suggests a positive outlook for INmune Bio. This could lead to increased investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100